IRIS
SERVETTO, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.691
EU - Europa 1.960
NA - Nord America 1.838
SA - Sud America 282
AF - Africa 69
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.846
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.746
SG - Singapore 1.064
RU - Federazione Russa 797
IT - Italia 632
CN - Cina 598
VN - Vietnam 508
BR - Brasile 224
HK - Hong Kong 188
DE - Germania 157
IN - India 96
FR - Francia 79
FI - Finlandia 76
JP - Giappone 60
CA - Canada 58
NL - Olanda 55
GB - Regno Unito 42
KR - Corea 42
AR - Argentina 30
CI - Costa d'Avorio 27
BD - Bangladesh 26
PL - Polonia 23
UA - Ucraina 20
ZA - Sudafrica 19
IE - Irlanda 17
PK - Pakistan 17
MX - Messico 15
PH - Filippine 13
ES - Italia 12
ID - Indonesia 11
IQ - Iraq 10
SE - Svezia 10
TH - Thailandia 10
LT - Lituania 9
UZ - Uzbekistan 9
EC - Ecuador 8
TR - Turchia 7
VE - Venezuela 7
BE - Belgio 6
IL - Israele 6
MY - Malesia 6
AT - Austria 5
EG - Egitto 5
TN - Tunisia 5
CL - Cile 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
PY - Paraguay 4
DZ - Algeria 3
GR - Grecia 3
IR - Iran 3
JM - Giamaica 3
RS - Serbia 3
SA - Arabia Saudita 3
AU - Australia 2
AZ - Azerbaigian 2
BO - Bolivia 2
BS - Bahamas 2
CO - Colombia 2
GT - Guatemala 2
HN - Honduras 2
KE - Kenya 2
MA - Marocco 2
PT - Portogallo 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
BF - Burkina Faso 1
BG - Bulgaria 1
CG - Congo 1
CH - Svizzera 1
CY - Cipro 1
EE - Estonia 1
ET - Etiopia 1
GY - Guiana 1
HU - Ungheria 1
KN - Saint Kitts e Nevis 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
NI - Nicaragua 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PG - Papua Nuova Guinea 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
YE - Yemen 1
YT - Mayotte 1
ZM - Zambia 1
Totale 6.846
Salva come PNG Salva come JPEG
Città #
Singapore 539
San Jose 343
Naples 218
Hefei 214
Ashburn 197
Moscow 188
Hong Kong 177
Ho Chi Minh City 162
Beijing 152
Hanoi 100
Dallas 93
Chandler 90
Munich 79
Santa Clara 77
The Dalles 56
Tokyo 55
Lauterbourg 49
Napoli 48
Kochi 45
New York 43
Los Angeles 42
Turku 42
Amsterdam 38
Seoul 37
São Paulo 31
Da Nang 27
Redondo Beach 25
Rome 25
Millbury 24
Boston 23
Buffalo 23
Haiphong 23
Toronto 22
Helsinki 20
Frankfurt am Main 18
Council Bluffs 17
Brooklyn 16
Des Moines 16
Falkenstein 16
Lawrence 16
Seattle 16
Warsaw 16
Orem 15
Montreal 13
Pune 13
London 12
Milan 12
Nuremberg 12
Formia 11
Johannesburg 11
Mexico City 11
Houston 10
Nanjing 10
Princeton 10
Shanghai 10
Chennai 9
Hicksville 9
Ninh Bình 9
Pozzuoli 9
Turin 9
Atlanta 8
Chicago 8
Hải Dương 8
San Mateo 8
Stockholm 8
Tashkent 8
Belo Horizonte 7
Genoa 7
Modica 7
Ottawa 7
Poplar 7
Biên Hòa 6
Can Tho 6
Guayaquil 6
Lappeenranta 6
Wilmington 6
Baghdad 5
Boardman 5
Bologna 5
Changsha 5
Charlotte 5
Denver 5
Düsseldorf 5
Huế 5
Islamabad 5
Kuala Lumpur 5
Lahore 5
Long Xuyen 5
Maceió 5
Nanchang 5
Quảng Ngãi 5
Quận Ba 5
Salvador 5
Angri 4
Brasília 4
Brussels 4
Bắc Giang 4
Campi Bisenzio 4
Caserta 4
Dong Ket 4
Totale 3.879
Salva come PNG Salva come JPEG
Nome #
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors 213
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 165
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 164
1599P - Effects of Hedgehog signaling inhibition on epithelial-stromal interactions in triple negative breast cancer cells 162
C-Src and EGFR inhibition in molecular cancer therapy: What else can we improve? 161
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 160
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 159
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 152
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 151
Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors 146
Mechanisms of resistance to mTOR inhibitors 144
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges 142
Tumour microenvironment and immune evasion in EGFR addicted NSCLC: Hurdles and possibilities 142
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 142
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 140
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. 140
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 140
P0081 Src inhibitors act through different mechanisms to cooperate with EGFR or MEK inhibitors in NSCLC models sensitive or resistant to erlotinib 139
Early assessment of IL8 and PD1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma 138
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers 137
KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies 136
DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review 136
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 135
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 134
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges 133
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. 132
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells 130
Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer 129
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 129
Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study 129
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study 129
ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors 126
EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 123
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC 123
Case report: Potential role of immunotherapy in thymic malignancies: a unique case of a durable and complete response upon an immune checkpoint inhibitor 115
Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: A case report 115
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. 114
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies 109
FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer 106
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers 104
Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes 104
Blinded independent central review versus local investigator assessment of PFS in RCTs of immunotherapy in advanced cancers: A systematic review and meta-analysis 104
Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review 97
RNA-Based Next-Generation Sequencing in Non-Small Cell Lung Cancer patients: data from Campania, Italy 97
AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors 92
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer 92
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer 82
Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904) 81
Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ERþ breast cancer 78
FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors 74
FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer 70
Malignant granular cell tumor of chest wall: a case report 69
Texture Analysis of 68Ga-DOTATOC PET/CT Images for the Prediction of Outcome in Patients with Neuroendocrine Tumors 69
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity 68
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy 67
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer 67
Breast-cancer specific comprehensive archive of Patient-Reported Outcome Measures (PROMs) for clinical research and clinical practice in oncology: Results from the PRO4All project 49
Prognostic Value of Tumor Dissemination (Dmax) Derived from Basal 18F-FDG Positron Emission Tomography/Computed Tomography in Patients with Advanced Non-Small-Cell Lung Cancer 38
Circulating innate lymphoid cells and IL-18 as potential immune biomarkers in thymic tumors 19
Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis 7
CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer 7
APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer 6
Performance of Control Arms in Trials Leading to FDA Cancer Drug Approvals 5
Correlation of ORR and PFS with OS outcomes in phase III trials of immunotherapy in advanced NSCLC: Systematic review and meta-analysis 4
Censoring in trials testing immunotherapy in advanced cancers: a systematic review and a meta-research study 4
Impact of relative dose intensity of first-line platinum-based chemotherapy in patients with thymic epithelial tumors: a retrospective study 3
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 3
Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanoma 3
Evaluating quality of life in thoracic malignancy trials: A scoping review on ESMO-MCBS quality of life checklist adherence and concordance with progression-free and overall survival 3
Novel applications of liquid Biopsy: Comprehensive methodology for circulating biomarker exploration in peripheral blood 2
Health-related quality of life assessment in trials testing tyrosine kinase inhibitors or immune checkpoints inhibitors in early-stage NSCLC 2
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis 2
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis 2
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 2
Quality of life results and survival outcomes in trials of immunotherapy in advanced cancers: A systematic review and meta-research study 2
Predictive role of functional respiratory tests in LUng toxicity in stage III NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL 1
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti-tumor immune response in peripheral immune cells of NSCLC patients 1
Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM) 1
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry 1
Totale 7.002
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.278
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.278
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202111 0 0 0 0 0 0 0 0 0 0 0 11
2021/2022183 5 0 8 10 4 9 4 4 32 17 38 52
2022/2023347 35 11 15 9 45 36 14 31 51 42 34 24
2023/2024352 14 34 61 22 17 54 23 36 9 10 47 25
2024/20251.939 51 68 4 79 51 121 192 141 91 239 734 168
2025/20263.890 385 350 497 357 594 176 416 194 476 229 179 37
Totale 7.002